Daniel Umbricht Selected Research

(4- (3- fluoro- 5- trifluoromethylpyridin- 2- yl)piperazin- 1- yl)(5- methanesulfonyl- 2- (2,2,2- trifluoro- 1- methylethoxy)phenyl)methanone

8/2018	Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient.
1/2016	Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin.
6/2014	Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel Umbricht Research Topics

Disease

16	Schizophrenia (Dementia Praecox) 01/2020 - 01/2003
5	Autism Spectrum Disorder 12/2020 - 08/2017
5	Psychotic Disorders (Schizoaffective Disorder) 05/2016 - 03/2009
3	Autistic Disorder (Autism) 12/2020 - 08/2017
2	Mental Disorders (Mental Disorder) 01/2021 - 08/2018
2	Treatment-Resistant Schizophrenia 03/2017 - 05/2016
2	Cognitive Dysfunction 01/2013 - 05/2003
2	Alzheimer Disease (Alzheimer's Disease) 05/2003 - 09/2002
1	Tremor (Tremors) 01/2021
1	Movement Disorders (Movement Disorder) 01/2021
1	Parkinson Disease (Parkinson's Disease) 01/2021
1	Disease Progression 01/2021
1	Hypokinesia (Bradykinesia) 01/2021
1	Major Depressive Disorder (Major Depressive Disorders) 01/2020
1	beta-Thalassemia (Cooley's Anemia) 08/2018
1	Syndrome (Syndromes) 05/2016
1	Tachycardia (Tachyarrhythmias) 05/2016
1	Tobacco Use Disorder (Nicotine Dependence) 01/2013
1	Hallucinations (Hallucination) 11/2011
1	Prodromal Symptoms 08/2009
1	Weight Gain 01/2007
1	Dementia (Dementias) 05/2003
1	Amyloid Plaque 05/2003
1	Nervous System Diseases (Neurological Disorders) 09/2002
1	Genetic Predisposition to Disease (Genetic Predisposition) 09/2002

Drug/Important Bio-Agent (IBA)

6	Antipsychotic Agents (Antipsychotics)IBA 01/2020 - 02/2003
5	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 06/2014 - 01/2003
4	Biomarkers (Surrogate Marker)IBA 12/2020 - 08/2017
4	Pharmaceutical PreparationsIBA 12/2020 - 08/2018
3	(4- (3- fluoro- 5- trifluoromethylpyridin- 2- yl)piperazin- 1- yl)(5- methanesulfonyl- 2- (2,2,2- trifluoro- 1- methylethoxy)phenyl)methanoneIBA 08/2018 - 06/2014
3	N-Methylaspartate (NMDA)IBA 02/2013 - 01/2003
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2002
2	Dopamine (Intropin)FDA LinkGeneric 01/2021 - 08/2009
2	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 01/2019 - 08/2017
2	Glycine (Aminoacetic Acid)FDA LinkGeneric 08/2018 - 06/2014
2	(6- chloro- 1- (2- (dimethylamino)ethyl)indol- 3- yl)- spiro(1H- isobenzofuran- 3,4'- piperidine)- 1'- yl- methanoneIBA 08/2017 - 08/2017
2	Vasopressins (Vasopressin)IBA 08/2017 - 08/2017
2	Risperidone (Risperdal Consta)FDA LinkGeneric 05/2016 - 06/2014
1	Monoamine Oxidase (MAO)IBA 01/2021
1	alpha-SynucleinIBA 01/2021
1	Serotonin and Noradrenaline Reuptake InhibitorsIBA 01/2020
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 01/2020
1	Serotonin (5 Hydroxytryptamine)IBA 01/2020
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2020
1	Antidepressive Agents (Antidepressants)IBA 01/2020
1	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 01/2020
1	mesoglycanIBA 01/2019
1	Biological ProductsIBA 01/2018
1	Glycine Plasma Membrane Transport ProteinsIBA 01/2018
1	Clozapine (Clozaril)FDA LinkGeneric 05/2016
1	N- ((3S)- 1- azabicyclo(2.2.2)oct- 3- yl)- 1H- indazole- 3- carboxamide hydrochlorideIBA 06/2014
1	Aripiprazole (Abilify)FDA Link 06/2014
1	Paliperidone Palmitate FDA Link 06/2014
1	Metabotropic Glutamate 5 ReceptorIBA 01/2013
1	Nicotine FDA Link 01/2013
1	Glutamate Receptors (Glutamate Receptor)IBA 09/2012
1	Phencyclidine (Angel Dust)IBA 09/2012
1	Cholinergic Antagonists (Anticholinergics)IBA 11/2011
1	AntibodiesIBA 05/2003
1	Amyloid beta-PeptidesIBA 05/2003
1	Serotonin 5-HT2 Receptor AgonistsIBA 01/2003
1	Ketamine FDA LinkGeneric 01/2003
1	Psilocybin (Psilocibin)IBA 01/2003
1	Tissue Inhibitor of MetalloproteinasesIBA 09/2002
1	Tissue Inhibitor of Metalloproteinase-1IBA 09/2002

Therapy/Procedure

3	Ambulatory Care (Outpatient Care) 11/2014 - 03/2009
2	Therapeutics 01/2019 - 01/2013
1	Time-to-Treatment 05/2016
1	Self Administration (Administration, Self) 01/2013
1	Polypharmacy 11/2011
1	Activities of Daily Living (ADL) 05/2003